cyrilzakka/clinical-trials huggingface dataset:
Stellate Gnaglion Block in Refractory Bell's Palsy

Idiopathic facial nerve palsy (Bell's palsy) is caused by damage to the facial nerve at any site of the peripheral branches after the facial nucleus.Stellate ganglion block is inteneded to increase blood flow and promotes nerve regeneration.

the conventional systemic corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve ineffective.

Our purpose in this study is to evaluate therapeutic effects of stellate ganglion block (SGB) on idiopathic persistant facial nerve palsy.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed by clinical and neurological assessment as one-sided idiopathic facial palsy
* Age 18 to 60
* ASA Ⅰ\~Ⅲ

Exclusion Criteria:

* diabetic
* coagulation dysfunction
* mental or cognitive dysfunclion
* allergy to injected medication
SJM Brady MRI Post Approval Study

The purpose of this post approval study is to evaluate the long-term safety of the FDA approved St. Jude Medical Tendril MRI™ lead implanted with a SJM Brady MRI implantable pulse generator (IPG) such as the Accent MRI™, Assurity MRI™, Endurity MRI™ pacemaker, or similar model (SJM Brady MRI System) in subjects with a standard bradycardia pacing indication.

This is a prospective, multi-center clinical study designed to evaluate the long-term safety of the Tendril MRI™ lead implanted with any SJM Brady MRI pacemaker or similar model (SJM Brady MRI system) in subjects with a standard bradycardia pacing indication through 60 months of follow up.

Additionally, the study will assess the safety of the pacemaker system in subject(s) undergoing clinically indicated MRI scan(s). Any enrolled subject implanted with the SJM Brady MRI system may be included in this evaluation if they are scheduled for or planning to have a MRI scan during the course of the study.

Eligibility Criteria:
Inclusion Criteria:

1. Subject is able to provide informed consent for study participation (legally authorized representative is NOT acceptable).
2. Subject is at least 18 years of age or of legal age to give informed consent specific to state and national law.
3. Subject meets at least one of the following criteria:

   1. Is an Accent MRI IDE study subject who is being rolled over into the SJM Brady MRI PAS and still has at least one Tendril MRI™ lead implanted with a SJM Brady MRI pacemaker such as the Accent MRI or similar model.
   2. Is a subject who has been implanted with at least one Tendril MRI lead and a SJM Brady MRI pacemaker such as the Accent MRI or similar model, but is not part of the Accent MRI IDE study and will be enrolled within 30 days after implant.
   3. Is a subject who will be implanted with at least one Tendril MRI lead and a SJM Brady MRI pacemaker such as the Accent MRI or similar model and will be consented either at or within 30 days before implant.
4. Subject is willing and able to comply with the prescribed follow-up tests and schedule of evaluations including MRI scan procedures.

Exclusion Criteria:

1. Subject has been enrolled or intends to participate in a clinical drug and/or device study with an active treatment arm or that has any procedures, which could confound the results of this trial.
2. Subject is not expected to be able to complete the study follow up schedule or duration due to any health condition such as has malignancy, is deemed a candidate for transplant or Ventricular Assist Device, or in hospice care.
Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease

The purpose of this study is to evaluate the relationship between plasma DNA levels and micro- and macro-circulatory vascular remodelling in patients with sickle cell disease


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years.
* Homozygous SS or Sß0 sickle cell disease patients.
* Seen in consultation for an annual clinical and para-clinical evaluation of his/her disease.
* Stable clinical condition of the disease defined as the absence of severe vaso-occlusive crises (requiring hospitalisation or a visit to the emergency unit) in the previous month and absence of transfusion in the previous 3 months.

Exclusion Criteria:

* Other haemoglobinopathy
* Known diabetes.
* Recent administration of an anticoagulant treatment at curative doses (\< 48h before inclusion), or platelet-inhibiting drugs (less than 1 week prior to inclusion).
* Recent transfusion (less than 3 months prior to inclusion).
* Pregnancy or post-partum (first 40 days after giving birth).
* Recent consumption of alcohol (less than 10h), coffee (less than 3h), and tobacco (less than 36h) before inclusion.
* Known infection with hepatitis B, C, and HIV infection.
* Known cancer or progressive blood disease.
* Known haemostasis or coagulation disorders.
* Progressive inflammatory or infectious diseases.
* Recent history (dating less than 3 months) of venous (pulmonary embolism, deep venous thrombosis) or arterial (acute coronary syndrome, stroke, peripheral arterial ischaemia) thromboembolic event.
* Adult patients subject to legal protection measures.
* Patients already involved in a therapeutic protocol.
* Patients not affiliated to a social security system.
* Non-inclusion criteria related to the technical requirements of the Endo-PAT:

  * Known cardiac arrhythmia.
  * Severe Raynaud's syndrome.
  * Hand or arm deformity that prevents an EndoPAT analysis.
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy

Angiotensin type-1 receptor (AT1R) blockers (ARBs) have been recognized recently as regulators of glucose and lipid metabolism in adipocytes and adipose tissue.Moreover telmisartan and irbesartan have been recognized recently as regulators of glucose metabolism. For ARB losartan, the results were controversial. To confirm its effect on glucose metabolism, we designed and performed a prospective, randomized and controlled study in subjects with type 2 diabetes and nephropathy.

Angiotensin II (AngII), the main effector peptide of the rennin-angiotensin system (RAS), is implicated in the development of vascular, cardiac, and renal pathologies. Several lines of evidence have suggested that AngII can impair insulin sensitivity.Angiotensin type-1 receptor (AT1R) blockers (ARBs) have been recognized recently as regulators of glucose and lipid metabolism in adipocytes and adipose tissue. Recent clinical trials suggest that blockade of the RAS, either by inhibiting the angiotensin-converting enzyme (ACE) or by blocking AT1R, may substantially lower the risk for type 2 diabetes. In the Heart Outcomes Prevention Evaluation (HOPE) trial, there was 34% reduction in relative risk for the development of type 2 diabetes. Similarly, in the Intervention For Endpoint Reduction in Hypertension study (LIFE), the incidence of type 2 diabetes was reduced by 25% in the losartan group compared with other antihypertensive therapies. Previous study demonstrated that AT1R blockade improved insulin sensitivity in animal models of insulin resistance. The underlying mechanism of the insulin sensitizing and anti-diabetic effect of ARBs is incompletely clear.

The nuclear hormone receptor peroxisome proliferator activated receptor- (PPAR-γ) plays an important role in the regulation of insulin sensitivity. Several studies have shown the ARBs telmisartan and irbesartan potently induces PPAR-γ activity, promoting PPAR-γ-dependent differentiation in adipocytes. However, not all ARBs own PPAR-γ activating properties. In vitro studies have shown that significant differences among PPAR-γ activating ARBs are likely caused by their physicochemical properties, and high lipophilicity is required to obtain sufficiently high penetration rates to bind to intracellular PPAR-γ. Losartan at high concentrations could activate PPAR-γ and behaved like partial PPAR-γ agonists. Nevertheless the results of losartan on insulin sensitivity remain controversial.

To elucidate the underlying effects of losartan on insulin sensitivity, we investigated the effects of losartan on insulin sensitivity and secretion in patients with type 2 diabetes and nephropathy.

Eligibility Criteria:
Inclusion Criteria:

* Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L
* 2h plasma glucose level of 7.5-13 mmol/L
* Body mass index (BMI) of 22 kg/m2
* Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is \>150mg.
* Informed consent

Exclusion Criteria:

* Type1 diabetes or nondiabetic renal disease
The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients

The purpose of the study is to determine the impact of a specific nutrition formula with a high content of eicosapentaenoic acid (EPA) and fat in oncology patients receiving radio-/chemotherapy on body weight, body composition, nutritional status and physical function compared to a standard nutrition formula. Using an adaptive design approximately 80 patients will be randomized in the first part of the study. Following an interim analysis further 160 patients may be added, for a total of 240 patients.


Eligibility Criteria:
Inclusion Criteria:

* patients with head \& neck cancer or oesophagus cancer,
* enteral nutrition with PEG at least for 14 weeks,
* cancer patients who receive a combined radio-/chemotherapy,
* start of nutritional therapy latest at beginning of the radio-/chemotherapy, body mass index \>=16 and \<=30 kg/m2,0
* Kondrup Score\>=3 or SGA = B/C,
* life expectancy \> 6 months,
* written informed consent.

Exclusion Criteria:

* second active carcinoma,
* severe diarrhea unresponsive to codeine/loperamide,
* positive anti-HIV-test (safety reasons),
* pregnant or lactating women,
* insulin-dependent diabetes mellitus type I and II,
* patients with cardiac pacemaker,
* allergy to contents of the investigational product, to milk protein or to fish oil,
* patient has no PEG,
* participation in concurrent clinical studies with any other investigational nutritional therapy within one months prior to start of the study,
* intake of muscle growth supportan substances (e.g. anabolics),
* additional fish oil or EPA substitution within the last 4 weeks, SGA status A (well nourished).
An Epidemiological Survey of Cancer-related Fatigue Among Taiwanese Gynecologic Cancer Patients

This study aim is to examine the prevalence, severity, and management of CRF among Taiwanese gynecologic cancer patients.

The cross-sectional survey is conducted at oncology inpatients unit and outpatients clinics of hospitals in Taiwan. Furthermore, the results will elucidate not only the epidemiology of CRF in Taiwan, but will supply physicians with more understanding about CRF, and help them to enhance the quality on cancer care to being perfected in the future.

Eligibility Criteria:
Inclusion Criteria:

* Patients who signed the informed consent form
* The age of eligible patients should be ≥ 20 years old.
* Inpatients or outpatients who have been given a diagnosis of gynecologic cancer.
* Able to communicate verbally and completely fill out the questionnaires

Exclusion Criteria:

* Patients who have been given a diagnosis of cognitive impairment are unable to complete the questionnaires
Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials

The purpose of this research study is to study a device called an electroencephalograph (EEG) in the diagnosis of treatment of attention deficit hyperactivity disorder (ADHD) in adults. People with ADHD have symptoms such as difficulty sustaining attention, organizing, and managing impulsivity. They can have trouble in school, at work, and at home. Subjects with ADHD who participate in this study will be given a once daily stimulant medication called osmotic release methylphenidate (Concerta) for 6 weeks, and have EEG testing done before and after the treatment period. Subjects will perform a computer based cognitive task during EEG testing. The U.S. Food and Drug Administration has approved osmotic release methylphenidate (Concerta) for the treatment of ADHD in adults and children. Similar procedures, without medication, will be performed with a sample of healthy adults without ADHD.


Eligibility Criteria:
ADHD Subjects

Inclusion Criteria:

* Male and female outpatients, aged 18-55 years
* Subjects meeting full criteria for the diagnosis of DSM-IV (Diagnostic and Statistical Manual, Version 4) Attention Deficit Hyperactivity Disorder (ADHD)
* Absence of pharmacological treatment for ADHD for at least one week.
* Right handedness

Exclusion Criteria:

* Any other current psychiatric or medical condition determined to be clinically significant.
* Current use of psychotropics or any medication with clinically significant CNS (Central Nervous System) effects.
* Mental retardation (IQ \< 80).
* Significant sensory deficits such as deafness or blindness.
* Individuals with a history of substance dependence or abuse within the past 6 months.
* Pregnant or nursing females.
* Subjects with pre-existing structural cardiac abnormalities.
* Clinically significant abnormal laboratory values, electrocardiogram or blood pressure reading

Healthy Control Subjects

Inclusion Criteria:

* Males and females, aged 18-55 years
* Subjects who do not meet full criteria for the diagnosis of DSM-IV Attention Deficit Hyperactivity Disorder (ADHD), as determined by clinical evaluation and/or ADHD module of structured diagnostic interview, completed by the study clinician.
* Right handedness

Exclusion Criteria:

* Any current psychiatric or medical condition determined to be clinically significant.
* Current use of psychotropics or any medication with clinically significant CNS effects.
* Mental retardation (IQ \< 80).
* Significant sensory deficits such as deafness or blindness.
Effects of Judo- Specific Injury Prevention Exercise Programme Judo Athletes

The study aimed to determine whether the judo-specific injury prevention exercise program had a significant positive effect on the performance of recreational judo athletes, with a particular focus on those employing the ippon technique.

The significant results obtained from our study are considered to be originated from the duration, scope, frequency, severity and content of training.

Eligibility Criteria:
Inclusion Criteria:

* Recreational judo athletes aged 18 to 35 years.
* Participants with at least one year of regular participation in recreational judo Athletes with no existing major musculoskeletal injuries or chronic health conditions that would limit their ability to participate in the prescribed exercise program.
* Participants willing to provide informed consent and commit to the duration of the study, including regular attendance at training sessions and data collection activities.
* Athletes engaging in judo training at least twice a week.

Exclusion Criteria:

* Athletes below 18 or above 35 years of age.
* Novice judo practitioners with less than one year of regular training.
* Individuals with a history of significant musculoskeletal injuries in the past six months or chronic conditions affecting their ability to participate fully.
* Participants unwilling or unable to provide informed consent or commit to the study requirements.
* Athletes participating in judo training less than twice a week, as they may not represent a group with sufficient exposure to the injury prevention program.
* Professional or highly competitive judo athletes, as their training regimens and performance levels may differ significantly from recreational athletes.
A Stepped Care Approach to Treating Dental Fear

The purpose of this study is to compare an intervention for dental fear to the usual approach (i.e., whatever participants' dentist typically does to help participants manage their fear). The dental fear intervention has 2 separate steps. Step 1 (the less intensive or 'light touch' intervention step) involves using a mobile application (app). Step 2 consists of a one-hour telehealth session with a mental health provider tailored to individualized dental fear.

This is a randomized study. The time spent participating in the study will depend on which study condition(s) participants are randomly assigned to. Because this study compares the dental fear intervention to the standard approach, 25% of participants will not get the intervention during the study period. These participants (called controls) will be offered the opportunity to provide feedback about their experiences with dentists. Participants will be offered the intervention free of charge at the conclusion of the study.

For each step of the intervention (Dental FearLess app or one-on-one session) relative to treatment as usual, the investigators hypothesize that participants will show greater declines in self-reported dental fear and improved oral health-related quality of life at post-treatment and follow-up period. De-identified attendance records will be collected from dental practices.


Eligibility Criteria:
Inclusion Criteria:

* Provide signed and dated informed consent form
* Willing to comply with all study procedures and be available for the duration of the study
* Adult, at least 18 years old.
* Score 4 or above on the Gatchel single-item dental fear rating scale
* Willingness to allow access to dental attendance records
* Access to a smartphone or tablet

Exclusion Criteria:

Given the scope and nature of the study, there is no exclusion criteria.
Effect of Exercise on Biomarkers in SCT

This study measures the effect of exercise on a variety of biomarkers in blood and urine selected to evaluate the physiological pathways of hemolysis, myolysis, thrombosis, inflammation, and renal function in subjects with sickle cell trait. These pathways have been shown to be associated with adverse events in athletes and warfighters with SCT upon protracted, repeated, strenuous exertion. Changes in biomarkers post-exercise compared to pre-exercise (and compared to healthy controls) suggest activation of the associated pathway(s) which may contribute to exercise-related events in athletes and warfighters and subclinical complications in non-athletes.

Subjects with sickle cell trait and healthy controls will be subjected to a single bout of moderate, controlled exercise on a treadmill. Blood and urine samples will be collected before exercise, immediately after exercise, and 24 hours after exercise. Fifteen biomarkers, three selected to evaluate each of the five physiologic pathways previously listed, will be tested at each of the three time points. Abnormal biomarkers before exercise suggest chronic pathway activation while exacerbated levels after exercise suggest further activation stimulated by exercise. Biomarker levels 24 hours post-exercise will be used to evaluate continued pathway activation or pathway recovery. By definition, 95% of health controls will show normal biomarker levels pre-exercise and biomarker patterns post-exercise will serve as the expected standard by which to compare the test subjects.

Eligibility Criteria:
Inclusion Criteria: Sickle Cell Trait Group (AS)

* Health subjects with sickle cell trait (AS)
* Ages 18-70 years

Inclusion Criteria: Control group (AA)

* Healthy subjects without sickle cell trait (AA)
* Ages 18-70 years

Exclusion Criteria: Sickle Cell Trait group (AS) AND healthy controls (AA).

Subjects will be excluded if they:

* weigh less than 110 pounds,
* are pregnant,
* have hemoglobinopathies (other than sickle cell trait) as determined by Hb electrophoresis,
* have other self-reported conditions known to cause blood coagulation activation, myocyte destruction, hemolysis, chronic inflammation, or renal disease
* any condition that places subjects at risk during exercise.
A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m\^2, and cisplatin 75 mg/m\^2 on Day 1 of each 3-week cycle for a maximum of 6 cycles.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, ≥ 18 years of age.
* Stage IIIb or IV non-small cell lung cancer.
* Chemotherapy-naive.

Exclusion Criteria:

* Previous treatment for non-small cell lung cancer.
* Previous malignant tumor within last 5 years, except for basal cell skin cancer or preinvasive cervical cancer.
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to start of study.
* Recent or current chronic treatment with aspirin (\> 325 mg/day).
Modified TIP (Snodgrass) Using Interrupted Sutures in Hypospadias

Using interrupted sutures in TIP technique by Snodgrass in repair of hypospadias instead of continuous sutures


Eligibility Criteria:
Inclusion Criteria:

* Midshaft , distal ,
* coronal hypospadias

Exclusion Criteria:

-
The Effects of Butyrate Enemas on Visceral Perception

During this double blind, placebo controlled, randomised cross over study, healthy volunteers received an enema once daily for one week containing either placebo (saline), 50mM butyrate or 100mM of butyrate. Before and directly after each test period a barostat protocol was performed to measure parameters for visceral perception.


Eligibility Criteria:
Inclusion Criteria:

* healthy

Exclusion Criteria:

* age, under 18 or over 65
* use of pre- or probiotics during study and 3 months previous to study
* previous bowel complaints
* gastrointestinal disease or abdominal surgery
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With minimal residual disease.

Patients of acute myeloid leukemia after chemotherapy with MRD(minimal residual disease) will receive NK cell infusion combined with consolidation chemotherapy. The bone marrow morphology and MRD remission of the patients will be observed 15 days after the same treatment. All patients will be followed up for 1 year.

NK cells are prepared in Beijing iCELL Biotechnology Co.,Ltd, which is subsidiary to Shanghai iCELL Biotechnology Co.,Ltd.

Eligibility Criteria:
Inclusion Criteria:

1. Patients diagnosed with acute myeloid leukemia;
2. MRD after 2 course of standard chemotherapy;
3. No plan for hematopoietic stem cell transplantation;
4. Hemoglobin (Hb) \>=60g/L, white blood cell count (WBC) \>=2.5x10\^9/L, platelet count \>=30x10\^9/L;
5. Patients have self-knowledge ability and can sign informed and voluntary consent forms;
6. Patients or their clients, guardians of pediatric patients signed the informed and voluntary consent form and joined the study.

Exclusion Criteria:

1. Intracranial hypertension or unconsciousness;
2. Symptomatic heart failure or severe arrhythmia;
3. Respiratory failure;
4. With other types of malignant tumor diseases;
5. T lymphocytic acute leukemia;
6. Diffuse intravascular;
7. Serum creatinine and / or urea nitrogen \>=1.5 times the normal value;coagulation;
8. Serum total bilirubin \>=1.5 times the normal value;
9. Sepsis or other difficult-to-control infections;
10. Uncontrollable diabetes;
11. severe mental disorders;
12. WHO physical status classification \>=3;
13. People who are allergic to Interleukin-2;
14. Patients after organ transplant;
15. Pregnant and lactating women.